- Coherus BioSciences (CHRS -3%) and Baxter International (BAX +0.4%) amend their August 2013 collaboration agreement pertaining to the development and commercialization of CHS-0214, a biosimilar to Amgen's (AMGN +1%) Enbrel (etanercept). Certain milestones and funding obligations have been revised and the partnership has been expanded to include select pre-commercialization activities. The revised milestone payments may increase Baxter's funding obligations by ~$12M. It also has agreed to buy Coherus common stock in a private transaction.
Baxter and Coherus update collaboration agreement for Enbrel biosimilar
Recommended For You
More Trending News
About CHRS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CHRS | - | - |
Coherus BioSciences, Inc. |